The median tumour cell reductions in log steps were 3.7 (2.9-4.3) (n ‫؍‬ 13) (Isolex-50), 3.5 (2.6-4.3) (n ‫؍‬ 13) (MiniMACS) and 1.5 (0.9-2.9) (n ‫؍‬ 17) (Ceprate-LC). Results were compared statistically by univariate analysis. Purity was significantly (P Ͻ 0.05) better after Mini-MACS selection. Recovery rates were significantly different between all devices tested. Tumour cell purging was superior after immunomagnetic separation (P Ͻ 0.001). Tumour cell purging is a main objective of CD34 + selection in the autologous setting. Our in vitro data clearly indicate that immunomagnetic separation is more efficient in the prevention of accidental reinfusion of contaminating tumour cells compared to immunoaffinity. However, it is not yet known if the same results can be obtained with fresh contaminating tumour cells.
High-dose chemotherapy supported by autologous stem cell reinfusion for treatment of metastatic and high-risk female breast cancer is currently under investigation in several American and European studies. 1, 2, 3 Tumour cell contamination of autologous stem cell products has been described using immunocytochemistry, reverse transcriptase PCR and cell culture techniques in approximately one third of harvests with a range from 0% to 100%. [4] [5] [6] [7] The clonogenic and metastatic potential of tumour cells isolated from blood and autografts was demonstrated in cell culture assays and in nude mice. [8] [9] [10] The metastatic potential of accidentally retransplanted tumour cells could be investigated by gene marking of autografts prior to infusion followed by the detection of marked cells after relapse. 11 However, due to the poor transduction efficacy of epithelial cancer cells by gene transfer, a negative result would not exclude the possibility of relapse induction by accidentally reinfused tumour cells. Different approaches have been described to purge autografts of tumour cells. 12 A major problem of purging procedures using cytotoxic agents is the damage to haemopoietic progenitor cells with subsequent delay of engraftment, an increased incidence of severe infections due to prolonged neutropenia and bleeding complications due to thrombocytopenia. [13] [14] [15] Haemopoietic cells necessary for recovery after highdose therapy and progenitor support express the CD34 antigen on their surface. 16 These cells can easily be enriched by immunological methods using anti-CD34 antibodies and separation by biotin-streptavidin immunoaffinity or magnetic separation with paramagnetic microbeads. Rapid and safe engraftment after reinfusion of enriched CD34
+ cell fractions has been described by several investigators after allogeneic and autologous transplantation. 17, 18 The immunologic selection of CD34-positive cells has no toxic side-effects on haemopoietic stem cells and progenitors without prolongation of cytopenia after reinfusion.
Furthermore, CD34 positive-cell selection is a promising approach to reducing the incidence or mitigating the severity of graft-versus-host-disease in the allogeneic setting by adjusted or nearly complete T cell depletion. However, the major rationale for CD34-positive cell selection in autologous marrow and stem cell transplantation is a reduction or removal of contaminating tumour cells accidentally coharvested during leukapheresis to avoid their reinfusion after high-dose therapy. 19, 20 In this report we compare CD34 + cell enrichment, CD34 + cell recovery, and the efficacy of purging of experimentally seeded breast cancer cells from bone marrow and G-CSF-mobilised peripheral blood stem cell collections between three devices using immunoaffinity and magnetic microbeads for separation of anti-CD34 antibody-labelled CD34 + cells. We show that CD34 + enrichment leads to a decrease in the total number of contaminating tumour cells up to 4.3 log steps with reasonably high recovery of CD34-positive progenitor cells.
Material and methods

Bone marrow and leukapheresis samples
Aliquots of 21 bone marrow samples and 37 leukaphereses were obtained after informed consent. Nineteen volunteer donors and two patients with acute myeloid leukaemia underwent bone marrow harvests from the iliac crest under general or spinal anaesthesia without prior growth factor mobilisation. Thirty-seven leukapheresis aliquots were obtained from 18 patients after preceding 5-day G-CSF mobilisation with a daily dose of 10-24 g/kg body weight injected subcutanously. The underlying diagnoses of the stem cell donors were non-Hodgkin's lymphoma (n = 8), multiple myeloma (n = 3), sarcoma (n = 2) and Hodgkin's disease. Four patients were volunteer donors for allogeneic transplantation. Mononuclear cells were isolated from marrow and stem cell samples by Ficoll centrifugation following standard protocols. Most marrow and stem cell aliquots were too small to split them into three aliquots to run the three devices.
Cell lines and tumour cell spiking
The breast cancer cell lines MCF-7 and MDA-MB453 were used for tumour cell spiking experiments. The cell lines were purchased from the American Type Culture Collection (ATCC), Rockville, MD, USA, and cultured and maintained under the conditions recommended by ATCC. For spiking experiments, the cells were trypsinised to obtain single cell suspensions. Suspensions were checked by light microscopy. Density of tumour cells was calculated using a Neubauer chamber and mononuclear cell fractions of marrow, and leukapheresis samples were counted after Ficoll separation using a Coulter counter (Coulter, Krefeld, Germany). Leukapheresis and bone marrow samples were spiked with tumour cells MCF-7 and MDA-MB453 in logarithmic dilutions from 10 Ϫ3 (0.1% tumour cells) to 10
Ϫ7
(0.00001% tumour cells). For purging experiments tumour cells from 10 Ϫ3 to 10 Ϫ7 were performed for each device at least twice -once with each cell line -with higher concentrations being tested up to six times. Breast cancer cell lines were not mixed for experiments.
CD34
+ enrichment
The CD34 + cell enrichment systems Ceprate-LC, Isolex-50 and MiniMACS were purchased from CellPro (Munich, Germany), Baxter (Munich, Germany) and Miltenyi Biotec (Bergisch Gladbach, Germany), respectively. The systems were used according to the manufacturers' instructions.
Only gravity was used for cell flow through selection columns.
FACS analysis
The flow cytometric analyses were performed before and after CD34
+ cell selection on a FACScan flow cytometer (Becton Dickinson, Heidelberg, Germany). The instrument settings were established for linear amplification of light scatter and logarithmic amplification of fluorescence channels. The cells were stained following standard protocols with a phycoerythrin (PE)-coupled antibody (HPCA-2; Becton Dickinson) not interfering with the antibodies used for CD34 + enrichment and recommended by the suppliers of selection devices. Controls were performed with an antiisotype IgG 1 -PE antibody (Becton Dickinson). Signals were presented graphically as a dot plot and data were analysed with Lysis-II software (Becton Dickinson). 21 
Immunocytochemistry
Cytospin slides were prepared with a Shandon cytospin centrifuge (Shandon, Runcorn, UK). Two hundred thousand cells were spun onto each slide and one to five slides were prepared per sample. The number of slides available depended on the amount of recovered cells after CD34 + cell separation. Due to the limited CD34 + cell count available for immunocytochemistry, we could test for samples spiked with 10 Ϫ6 or 10 Ϫ7 cells only for relative tumour cell enrichment.
Slides were air-dried, fixed, and stored at Ϫ20°C. Tumour cells on cytospin slides were detected by the anticytokeratin antibody KL1 (Boehringer Mannheim, Mannheim, Germany) and subsequent APAAP (alkaline phosphatase anti-alkaline phosphatase) stain. Stained cytospin slides were evaluated by light microscopy, and the KL1-positive cells were counted. 22 
Data analysis
Data were analysed using the computer software Excel (Microsoft, Munich, Germany) and WinSTAT (Kalmia Co, Cambridge, MA, USA). For the comparison of the two groups, the independent t-test or the Mann-Whitney U test were used, and processing data from all devices were compared by univariate analysis. 
Results
Twenty
Purity of enriched CD34
+ cells
The median purity of enriched CD34 + cells was best after separation by MiniMACS (96.5%, 66.6-99.2%), followed by Isolex-50 (92.2%, 43.5-96.1%) and Ceprate-LC (77.9%, 31.4-93.6%). The differences were significant between MiniMACS and the other two devices (P Ͻ 0.05), but not between Isolex-50 and Ceprate-LC. The data are shown in Table 2 . Figure 1a shows the corresponding box and whisker diagram.
Recovery of enriched CD34
Recovery of immunologically enriched CD34
+ cells was best using the MinMACS device (69.9%, 39.1-100%), followed by Ceprate-LC (42.9%, 23.7-100%) and Isolex-50 (30.8%, 18.6-71.8%). The differences were significant between MiniMACS and the other two systems (P Ͻ 0.05) ( Table 2 and Figure 1b) .
Enrichment factor
The CD34
+ cell count per volume unit after selection divided by the CD34 + cell count before selection was defined as the enrichment factor. A large enrichment factor is a parameter for a small graft volume after selection. Considering all samples, the median enrichment was significantly (P Ͻ 0.001) better from leukaphereses (108-fold, 19-855) than from marrow (30-fold, 17-69); the differences between the devices were small and not significant. The median enrichment factor was 49.1 (17.9-353.5) for Ceprate-LC, 57.8 (18.6-191 .2) for Isolex-50 and 58.1 (17.0-854.6) for MiniMACS (Table 2 and Figure 1c ).
Purging
Tumour cell purging from marrow and leukapheresis samples was highest after separation by Isolex-50 with a median of 3.7 log (2.9-4.3) followed by MiniMACS (3.5 Table 2 Purity and recovery (in %) of CD34 + cell fraction separated from bone marrow and leukapheresis samples, factor of CD34 + cell enrichment and purging of breast cancer cells in logs (absolute tumour cell reduction)
Ceprate-LC MiniMACS
Isolex-50 log, 2.6-4.3); the differences were not significant. Purging by Ceprate-LC was significantly less effective with a median breast cancer cell depletion of 1.5 log (0.9-2.9). The differences between immunomagnetic and immunoaffinity separation were highly significant (P Ͻ 0.001). Data are shown in Table 2 and Figure 1d . For statistical reasons, experiments without recovered tumour cells after CD34 + selection were excluded from further analysis. This was observed, as expected, at dilutions of 10 Ϫ6 and 10
Ϫ7
. For ethical reasons it was impossible to increase the sample volume as would be necessary for a statistical evaluation of tumour cell dilutions of 10 Ϫ6 and 10 Ϫ7 and higher. Thus, in order to achieve an approximation for these conditions, we calculated regression curves from the available data shown in Figure 2a -c. This analysis suggests that the kinetics of depletion are more independent of tumour cell concentration for the Ceprate-LC than for the MiniMACS or Isolex-50 devices. The purging efficacy of all devices examined is better when samples with a higher tumour cell load were processed.
Comparison of marrow and blood stem cell processing
Comparing the processing data of all marrow and leukapheresis samples, only the CD34 + cell enrichment was significantly better from leukapheresis samples than from bone marrow (P Ͻ 0.05). Data are shown in Table 3 . Subanalysis for each device confirmed this significance for Ceprate-LC and MiniMACS subgroups. Because of the small number of experiments, results for blood and bone marrow have not been compared further.
Correlation of depletion, purity, recovery and CD34
+ cell enrichment Tumour cell depletion, purity of selected CD34
+ cell fraction, recovery of CD34 + cells and CD34 + cell enrichment were correlated using the Spearman rank test. Positive correlations were found between the CD34 + cell percentage of unselected samples and the purity after separation (correlation coefficient (coc) = 0.40, P = 0.002), and between the purity of selected CD34 + cells and the percentage of recovery (coc = 0.32, P = 0.014). A negative correlation was found between the CD34 + cell content of unselected samples and the CD34 + cell enrichment after selection (coc = Ϫ0.97, P Ͻ 0.001).
Discussion
Currently, at least three devices are available for the isolation and enrichment of CD34-positive cell populations from bone marrow and peripheral blood stem cell collections. The devices work either on an immunomagnetic basis or by immunoaffinity. The device separating CD34-positive cells by biotin-streptavidin immunoaffinity has been used widely for clinical graft processing. Magnetic bead-based systems are awaiting permission for clinical use. The question of which system is best for which purpose has not yet been examined. In this paper, we compare the capacities of three systems for CD34-positive cell selection and for tumour cell purging.
Purging by CD34
+ cell selection W Krüger et al In unprocessed samples, the median percentage of CD34 + cells was more than three times higher in bone marrow than in leukapheresis samples. The median mononuclear cell count per volume unit was nearly six-fold higher in leukapheresis samples than in bone marrow.
Fifty-eight samples were used for preparing tumour cell dilutions from 10 Ϫ3 to 10
Ϫ7
. All dilution steps were examined up to six times with each device. Tumour cells were searched on APAAP-stained cytospin slides after CD34-positive selection. Slides without visible tumour cells were excluded from statistical analysis. Purging by immunomagnetic devices was significantly better with a median of 3.6 and 3.5 log steps than by immunoaffinity with 1.5 log steps. Differences between both immunomagnetic devices were small and non-significant.
Anderson et al 23 described a 2.5 log reduction of breast cancer cells from bone marrow grafts by mafosfamide purging with a concentration of 80 g/ml. However, this mafosfamide concentration also killed 99% of haemopoietic progenitor cells in the in vitro study. A delay of engraftment is common after reinfusion of mafosfamidepurged autografts after high-dose therapy for acute myeloid leukaemia. 15 AML patients are commonly more intensively pre-treated than breast cancer patients. However, Shpall et al described the same phenomenon after mafosfamide purging of breast cancer autografts. In a subsequent clinical phase 1 trial, a significant delay in leukocyte recovery could be correlated with the mafosfamide concentration used for tumour cell purging. 24 The combination of mafosfamide incubation with immunotoxin treatment was examined by O'Briant et al 25 in an in vitro study. They described 2.2-5.4 log tumour cell reduction from a 1:10 breast cancer cell dilution in irradiated marrow cells. The mafosfamide concentration of 40 g/ml in combination with immunotoxins reduced CFU-GM growth to 37% after purging. Similar results obtained by combined purging were published by Anderson et al. 23 A one log step tumour cell reduction after etherlipid incubation in an experimental model was published by Dietzfelbinger et al. 13 A problem of all in vitro purging studies is the choice of the ratio of tumour:progenitor cells. Most investigators have worked with 10 Ϫ1 -10 Ϫ2 dilutions. These ratios allow excellent statistical analyses after purging experiments, but they do not reflect the clinical situation. Tumour cell contamination in vivo seems to occur in ratios of 10 Ϫ5 to 10
Ϫ6
or less. The purging kinetics -especially of immunological approaches -could be dependent to a greater or lesser degree on tumour cell concentration. The difficulty of examining purging approaches in realistic dilutions in vitro is the number of cells necessary for a reliable statistical analysis. For ethical reasons, it is impossible to use marrow or leukapheresis cells for large scale spiking experiments. Buffy coat cells of red cell donors could be used as an alternative, but probably not for CD34 + selection experiments to be compared with analyses of leukaphereses. Thus, we decided to examine dilutions of cancer cells in marrow or leukapheresis samples in log steps from 10 Ϫ3 up to 10
Ϫ7
. Due to the relatively small number of cells available for experiments, we excluded cytospin analyses from higher dilutions without visible tumour cells on cytospin slides from statistical analysis, but we could exclude a relative tumour cell enrichment per slide by this practice. Regression curves of tumour cell depletion against the tumour cell concentration for each device were calculated. The purging kinetics of CD34 + cell selection seem to be more independent of tumour cell concentration for cell selection by immunoaffinity than for immunomagnetic separation. However, regression graphs show, for all devices examined, that purging by CD34-positive cell selection is most effective for high tumour cell concentrations and less effective with declining tumour cell concentration. The question of whether a real negative purging of clinical grafts is possible by CD34-positive cell selection needs clarification.
We did not determine the capacity of the devices to deplete T lymphocytes for allogeneic graft processing. The minor differences in CD34
+ cell enrichment and the differences in purity of selected cells between the three devices indicate only slight differences in T cell depletion due to variations of graft volume after processing. Beyond that, the concept of a complete T cell depletion to preserve a graft-versus-leukaemia effect and to generate a sufficient host-immune system after allogeneic transplantation has been abandoned. 26, 27 However, to investigate purging efficacy for processing aphereses from patients with nonHodgkin's lymphoma, these experiments should be repeated determining the percentage of B and T lymphocytes before and after selection. The necessity of investigating these questions was recently supported by a paper from Hawkins et al, 28 who described -in contrast to our resultsthe highest purity of CD34 + cells selected from materials obtained from CML patients after immunoaffinity selection. Our results demonstrate that effective breast cancer cell purging from autografts is possible by immunomagnetic CD34-positive selection. The median tumour cell depletion by immunobead selection (3.5 log and 3.7 log) is inferior to the best results obtained by combined mafosfamide immunotoxin treatment (5.4 log), but since the clinical significance of accidental tumour cell reinfusion has not been clarified, patients should not be endangered by mafosfamide-induced prolongation of engraftment. Hopefully, the CD34 + selection can in future be combined with other purging techniques, eg antibody-based negative selection, to optimise depletion. A final comparison of different breast cancer cell purging procedures requires identical experimental settings and processing of realistic cancer cell concentrations in progenitor cells.
Our data clearly indicate the superiority of magnetic bead selection as compared to immunoaffinity selection for sufficient tumour cell purging in this model system. However, these data require proof with fresh leukaphereses samples contaminated with tumour cells and eventually testing in clinical studies.
